Eton Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $17 from $15 and keeps a Buy rating on the shares. Eton on Friday announced the acquisition of Galzin, an FDA approved therapy for maintenance of Wilson Disease in patients that have been initially treated with a chelating agent, from Teva (TEVA), the analyst tells investors in a research note. The company’s existing metabolic disease commercial sales force could support U.S. commercialization of Galzin resulting in modest contribution to long-term growth.